!!Pancras C.W. Hogendoorn - Selected Publications
\\
Hogendoorn has published over 430 peer-reviewed scientific publications (of which 143 as last author) and 37 book chapters; his h-index is 69 (Web of Science, March 2019) and the number of citations to his articles (excl. self-citations) is 16.082. Over 30 of his publications have more than 100 citations. \\
\\
1. Lancia C, Anninga JK, Sydes MR, Spitoni C, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M. A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. Cancer Chemother Pharmacol 2019.\\
\\
2. 2. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Hall KS, Isakoff MS, Jovic G, Kuhne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmeimann B, Sydes MR, Marina N. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer 2019;109:36-50.\\
\\
3. Fletcher CDM, Bridge J, Hogendoorn PCW, Mertens F (Eds). WHO Classification of tumours of soft tissue and bone. IARC: Lyon 2013; ISBN 978-92-832-2434-1 (editor and co-author)\\
\\
4. Hogendoorn PCW, Bovee JVMG, Nielsen GP. Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. In: CDM Fletcher, J Bridge, PCW Hogendoorn, F Mertens (Eds). WHO Classification of tumours of soft tissue and bone. IARC: Lyon 2013; ISBN 978-92-832-2434-1; p264-268 (book chapter)\\
\\
5. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briare-de Bruin I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PCW. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009;219:294-305 (IF: 6.25; cited: 151)\\
\\
6. Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ, Hogendoorn PCW. The NFATc2 gene is involved in a novel cloned translocation in a ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 2009;15:2259-2268 (IF: 10.19; cited 94)\\
\\
7. Bovée JVMG, Cleton Jansen AM, Taminiau AHM, Hogendoorn PCW. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005;6:599-607 (IF: 36.42; cited 100)\\
\\
8. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RMC, Hogendoorn PCW. Incidence of Gastrointestinal Stromal Tumours (GIST) is underestimated: results of a nation-wide study. Eur J Cancer 2005; 41:2868-2872 (IF: 7.19; cited 179)\\
\\
9. van Roggen, JFG; van Velthuysen, MLF; Hogendoorn, PCW. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001;54 (2):96-102 (IF: 2.89; cited 146)\\
\\
10. Bovee JVMG, Cleton-Jansen A-M, Wuyts W, Caethoven G, Taminiau AHM, Bakker E, van Hul W, Cornelisse CJ, Hogendoorn PCW. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999; 65:689-698 (IF: 8.86; cited 126)